pSivida enters new trials

LOCAL nanotechnology company pSivida has announced the release of the six-month results of its Phase II (a) trials of the BrachySil liver cancer therapy, allowing it to enter the next phase of dosing trials. Eight patients at Singapore General Hospital with advanced liver cancer were treated with the therapy, which directly targets radiotherapy into tumours, reducing side effects and greatly enhancing the killing of cancer cells, according to the company. The six-month data showed that tumour size was significantly reduced, said pSivida. The results extend those recorded after three months of therapy and also showed that BrachySil is safe and well tolerated.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
10th-The University of Notre Dame Australia6,708
47 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer